Abstract
The rapid development of nanotechnology requires the production of nanoparticles which are found in numerous novel products. To reduce the number of animal tests during the assessment of lung toxicity of airborne nanoparticles in vitro exposure systems and lung specific bioassays have been developed. The reproducible application of bioassays for exposure of lung cells at the air-liquid interface promises a higher efficiency and cost reductions in toxicological testing. Despite significant progress of the exposure technology and fundamentals of bioassays a stringent validation of the in vitro versus in vivo tests is still lacking.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal für Verbraucherschutz und Lebensmittelsicherheit
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
